Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates.

Minond D, Cudic M, Bionda N, Giulianotti M, Maida L, Houghten RA, Fields GB.

J Biol Chem. 2012 Oct 19;287(43):36473-87. doi: 10.1074/jbc.M112.389114. Epub 2012 Aug 27.

2.

Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates.

Stawikowska R, Cudic M, Giulianotti M, Houghten RA, Fields GB, Minond D.

J Biol Chem. 2013 Aug 2;288(31):22871-9. doi: 10.1074/jbc.M113.462267. Epub 2013 Jun 18.

3.

Glycosylation of a disintegrin and metalloprotease 17 affects its activity and inhibition.

Chavaroche A, Cudic M, Giulianotti M, Houghten RA, Fields GB, Minond D.

Anal Biochem. 2014 Mar 15;449:68-75. doi: 10.1016/j.ab.2013.12.018. Epub 2013 Dec 19.

4.

SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.

Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D.

J Med Chem. 2015 Aug 13;58(15):5808-24. doi: 10.1021/acs.jmedchem.5b00354. Epub 2015 Aug 4.

PMID:
26192023
5.

ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha.

Le Gall SM, Bobé P, Reiss K, Horiuchi K, Niu XD, Lundell D, Gibb DR, Conrad D, Saftig P, Blobel CP.

Mol Biol Cell. 2009 Mar;20(6):1785-94. doi: 10.1091/mbc.E08-11-1135. Epub 2009 Jan 21.

6.

Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening.

Moss ML, Rasmussen FH.

Anal Biochem. 2007 Jul 15;366(2):144-8. Epub 2007 May 3.

PMID:
17548045
7.

Functional role of N-glycosylation from ADAM10 in processing, localization and activity of the enzyme.

Escrevente C, Morais VA, Keller S, Soares CM, Altevogt P, Costa J.

Biochim Biophys Acta. 2008 Jun;1780(6):905-13. doi: 10.1016/j.bbagen.2008.03.004. Epub 2008 Mar 13.

PMID:
18381078
8.

The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?

Saftig P, Reiss K.

Eur J Cell Biol. 2011 Jun-Jul;90(6-7):527-35. doi: 10.1016/j.ejcb.2010.11.005. Epub 2010 Dec 30. Review.

PMID:
21194787
9.

The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.

Rapti M, Atkinson SJ, Lee MH, Trim A, Moss M, Murphy G.

Biochem J. 2008 Apr 15;411(2):433-9. doi: 10.1042/BJ20071430.

PMID:
18215140
10.

LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries.

Tucher J, Linke D, Koudelka T, Cassidy L, Tredup C, Wichert R, Pietrzik C, Becker-Pauly C, Tholey A.

J Proteome Res. 2014 Apr 4;13(4):2205-14. doi: 10.1021/pr401135u. Epub 2014 Mar 17.

PMID:
24635658
11.

Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.

Mezyk-Kopeć R, Bzowska M, Stalińska K, Chełmicki T, Podkalicki M, Jucha J, Kowalczyk K, Mak P, Bereta J.

Cytokine. 2009 Jun;46(3):309-15. doi: 10.1016/j.cyto.2009.03.002. Epub 2009 Apr 5.

PMID:
19346138
12.

Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells.

Ebsen H, Schröder A, Kabelitz D, Janssen O.

PLoS One. 2013 Oct 9;8(10):e76853. doi: 10.1371/journal.pone.0076853. eCollection 2013.

13.

The Antiatherogenic Effect of Fish Oil in Male Mice Is Associated with a Diminished Release of Endothelial ADAM17 and ADAM10 Substrates.

Speck N, Brandsch C, Schmidt N, Yazdekhasti N, Hirche F, Lucius R, Rimbach G, Stangl GI, Reiss K.

J Nutr. 2015 Jun;145(6):1218-26. doi: 10.3945/jn.115.211375. Epub 2015 Apr 29.

PMID:
25926412
14.

Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10.

Caescu CI, Jeschke GR, Turk BE.

Biochem J. 2009 Oct 23;424(1):79-88. doi: 10.1042/BJ20090549.

15.

ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein.

Moss ML, Powell G, Miller MA, Edwards L, Qi B, Sang QX, De Strooper B, Tesseur I, Lichtenthaler SF, Taverna M, Zhong JL, Dingwall C, Ferdous T, Schlomann U, Zhou P, Griffith LG, Lauffenburger DA, Petrovich R, Bartsch JW.

J Biol Chem. 2011 Nov 25;286(47):40443-51. doi: 10.1074/jbc.M111.280495. Epub 2011 Sep 28.

16.

Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism.

Bakken AM, Protack CD, Roztocil E, Nicholl SM, Davies MG.

J Vasc Surg. 2009 May;49(5):1296-303. doi: 10.1016/j.jvs.2008.12.026.

17.

The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.

Pruessmeyer J, Ludwig A.

Semin Cell Dev Biol. 2009 Apr;20(2):164-74. doi: 10.1016/j.semcdb.2008.09.005. Epub 2008 Sep 18. Review.

PMID:
18951988
18.

A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3).

Möller-Hackbarth K, Dewitz C, Schweigert O, Trad A, Garbers C, Rose-John S, Scheller J.

J Biol Chem. 2013 Nov 29;288(48):34529-44. doi: 10.1074/jbc.M113.488478. Epub 2013 Oct 11.

19.

Acetylenic inhibitors of ADAM10 and ADAM17: in silico analysis of potency and selectivity.

Healy EF, Romano P, Mejia M, Lindfors G 3rd.

J Mol Graph Model. 2010 Nov;29(3):436-42. doi: 10.1016/j.jmgm.2010.08.006. Epub 2010 Sep 21.

PMID:
20863729
20.

Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17.

Esselens CW, Malapeira J, Colomé N, Moss M, Canals F, Arribas J.

Biol Chem. 2008 Aug;389(8):1075-84.

PMID:
18979631
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk